Immunocore downgraded by Guggenheim
$IMCR
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Guggenheim downgraded Immunocore from Buy to Neutral
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/13/2024 | $74.00 → $35.00 | Overweight → Equal-Weight | Morgan Stanley |
| 11/11/2024 | $72.00 → $38.00 | Outperform → Neutral | Mizuho |
| 10/24/2024 | $24.00 | Sell | UBS |
| 10/7/2024 | Buy → Neutral | Guggenheim | |
| 4/29/2024 | $74.00 | Outperform | Leerink Partners |
| 11/20/2023 | $60.00 | Overweight | JP Morgan |
| 11/2/2023 | Overweight | Cantor Fitzgerald | |
| 10/31/2023 | $84.00 | Outperform | Robert W. Baird |
4 - Immunocore Holdings plc (0001671927) (Issuer)
4 - Immunocore Holdings plc (0001671927) (Issuer)
3 - Immunocore Holdings plc (0001671927) (Issuer)
Immunocore reports first quarter financial results and provides a business update KIMMTRAK® (tebentafusp-tebn) net revenues of $93.9 million in Q1 2025, growing by 33% year-over-year On track for Phase 3 TEBE-AM trial to complete enrollment in 1H 2026 On track for dose selection in Phase 3 PRISM-MEL-301 trial in 2H 2025 Initial multiple ascending dose data for HIV functional cure candidate presented during oral session at CROI 2025; dose escalation ongoing Cash, cash equivalents and marketable securities of $837 million as of March 31, 2025 (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md., US, May 7, 2025) Immunocore Holdings plc (NASDAQ:IMCR) ("Immunocore" or the "Com
Immunocore to present at upcoming investor conferences (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md., US, 02 April 2025) Immunocore Holdings plc (NASDAQ:IMCR) ("Immunocore" or the "Company"), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announced that management will participate in the following investor conferences in April. Kempen Life Sciences Conference 1x1 and small group meetings: Thursday, April 3, 2025 Needham Virtual Healthcare Conferen
Immunocore presents initial multiple ascending dose data for HIV functional cure candidate in an oral presentation at CROI 2025 IMC-M113V was well tolerated, with no dose-limiting toxicities Signals of dose-dependent reduction in active reservoir, and viral control after complete antiretroviral treatment interruption in some PLWH Enrollment in MAD portion of the trial continues with higher doses being evaluated (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md., US, 10 March 2025) Immunocore Holdings plc (NASDAQ:IMCR) ("Immunocore" or the "Company"), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically impr
4 - Immunocore Holdings plc (0001671927) (Issuer)
S-8 - Immunocore Holdings plc (0001671927) (Filer)
8-K - Immunocore Holdings plc (0001671927) (Filer)
10-Q - Immunocore Holdings plc (0001671927) (Filer)
Immunocore appoints Travis Coy, previously a Non-Executive Director, as its EVP, Chief Financial Officer and Head of Corporate Development (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md., US, 02 January 2025) Immunocore Holdings plc (NASDAQ:IMCR) ("Immunocore" or the "Company"), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announces that Travis Coy has been appointed as Executive Vice President (EVP), Chief Financial Officer and Head of Corporate Development, effective January 1, 2025. He will become an Exe
Leadership Team Strengthened as Clinical Development of LEVI-04 a Novel Neurotrophin Modulator for Osteoarthritis and Chronic Pain Advances SANDWICH, United Kingdom, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Levicept Ltd, a biotechnology company focused on the development of LEVI-04, a first-in-class treatment for chronic pain indications, today announces the appointment of Eliot Forster as CEO. Founder and inventor of LEVI-04, Simon Westbrook, is to take the role of CSO. Eliot brings more than thirty years of experience in the biotech and pharmaceutical sectors, with considerable experience in deal making and finance. His appointment strengthens the Levicept leadership team as the company matur
Immunocore Appoints Siddharth Kaul to its Board of Directors (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 9 June 2022) Immunocore Holdings plc (NASDAQ:IMCR) ("Immunocore" or the "Company"), a commercial-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, autoimmune and infectious diseases, today announces the appointment of Siddharth (Sid) Kaul as a non-Executive member of its Board of Directors, effective June 8, 2022. Sid will serve as a Class II director and also serve as a member of the Audit and Remuneration committees. Sid is a s
SC 13G/A - Immunocore Holdings plc (0001671927) (Subject)
SC 13G/A - Immunocore Holdings plc (0001671927) (Subject)
SC 13G/A - Immunocore Holdings plc (0001671927) (Subject)
Immunocore reports first quarter financial results and provides a business update KIMMTRAK® (tebentafusp-tebn) net revenues of $93.9 million in Q1 2025, growing by 33% year-over-year On track for Phase 3 TEBE-AM trial to complete enrollment in 1H 2026 On track for dose selection in Phase 3 PRISM-MEL-301 trial in 2H 2025 Initial multiple ascending dose data for HIV functional cure candidate presented during oral session at CROI 2025; dose escalation ongoing Cash, cash equivalents and marketable securities of $837 million as of March 31, 2025 (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md., US, May 7, 2025) Immunocore Holdings plc (NASDAQ:IMCR) ("Immunocore" or the "Com
KIMMTRAK (tebentafusp) Q4 net sales of $84.1 million and $310.0 million for full year 2024; continued growth expected in 2025 Executing on KIMMTRAK lifecycle management with two Phase 3 trials (TEBE-AM and ATOM) in additional melanoma indications Advancing PRAME portfolio – first patient randomized in Phase 3 PRISM-MEL-301; enrollment continues in Phase 1/2 trial of brenetafusp combinations in ovarian cancer and NSCLC; first patient dosed in Phase 1 trial of IMC-P115C (PRAME-A02-HLE) First patient dosed in Phase 1/2 trial of IMC-R117C (PIWIL1) in colorectal and other gastrointestinal cancers Will present initial Phase 1 multiple ascending dose HIV data for IMC-M113V in 1Q 2025 and Phase
(OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md., US, 19 February 2025) Immunocore Holdings plc (NASDAQ:IMCR) ("Immunocore" or the "Company"), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announced that it will report financial results for the fourth quarter and year ended December 31, 2024 on Wednesday, February 26, 2025. Following the announcement, the Company will host a live teleconference and webcast at 8:00 a.m. EST (1:00 p.m. GMT) to discuss its financial results and provide a business and portfolio u
Morgan Stanley downgraded Immunocore from Overweight to Equal-Weight and set a new price target of $35.00 from $74.00 previously
Mizuho downgraded Immunocore from Outperform to Neutral and set a new price target of $38.00 from $72.00 previously
UBS initiated coverage of Immunocore with a rating of Sell and set a new price target of $24.00